A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

Summary

This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with non-cirrhotic NASH/MASH and fibrosis stage 2 or 3 (F2 or F3). The study will enroll subjects in two cohorts for a total samples size of 1650 subjects.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• NASH With Fibrosis
• MASH With Fibrosis

Eligibility basics and study details

Study type

Interventional

Phase

Phase 3

Ages

18 to 80 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Akero Therapeutics, Inc

Last updated on ClinicalTrials.gov

October 15, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites

+9 more sites listed on ClinicalTrials.gov